Skip to search formSkip to main contentSkip to account menu

valrubicin

Known as: 2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-({2,3,6-trideoxy-3-[(trifluoroacetyl)amino]hexopyranosyl}oxy)-1,2,3,4,6,11-hexahydrotetracen-2-yl]ethyl pentanoate, N-Trifluoroacetyladriamycin-14-valerate, (8S, 10S)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-[[2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-?-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione 8²-valerate 
A semisynthetic derivative of the antineoplastic anthracycline antibiotic doxorubicin. With a mechanism of action that appears to differ from… 
National Institutes of Health

Related topics

Related topics

11 relations

Narrower (2)

AD 32Valtaxin

Broader (3)

Antineoplastic AgentsDoxorubicinTopoisomerase II Inhibitors
Bladder NeoplasmDrug AllergyNCIt Antineoplastic Agent TerminologyUrinary tract infection

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2020
Highly Cited
2020
Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study
The recent outbreak of novel coronavirus disease-19 (COVID-19) calls for and welcomes possible treatment strategies using drugs… 
Highly Cited
2000
Highly Cited
2000
Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.
PURPOSE We assess the efficacy and safety of intravesical valrubicin for the treatment of carcinoma in situ in patients with… 
Highly Cited
2000
Highly Cited
2000
EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER
Highly Cited
1986
Highly Cited
1986
Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice.
Previous studies have demonstrated that human leukemic cells and certain cancer cells in culture have a higher uptake of plasma… 
Highly Cited
1984
Highly Cited
1984
Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells…
Calmodulin inhibitors enhance cytotoxic effects of doxorubicin (DOX) in DOX-resistant (P388/DOX) P388 mouse leukemia cells by… 
Highly Cited
1981
Highly Cited
1981
Protein-associated DNA breaks and DNA-protein cross-links caused by DNA nonbinding derivatives of adriamycin in L1210 cells.
The effects of Adriamycin derivatives on L1210 mouse leukemia cells were studied with the DNA alkaline elution assay. The… 
Highly Cited
1980
Highly Cited
1980
Laser flow cytometric studies on the intracellular fluorescence of anthracyclines.
We have used a laser flow cytometer to excite and quantitate the intracellular fluorescence of cells exposed in vitro and in vivo… 
Highly Cited
1978
Highly Cited
1978
Effect of adriamycin and analogs on the nuclear fluorescence of propidium iodide-stained cells.
Adriamycin (ADR) and N-trifluoroacetyladriamycin-14-valerate, respectively, inhibit and enhance the nuclear fluorescence of cells… 
Highly Cited
1976
Highly Cited
1976
Differences in cellular uptake and cytofluorescence of adriamycin and N-trifluoroacetyladriamycin-14-valerate.
Adriamycin-specific fluorescence appears slowly in living cells and is localized in nuclei and chromosomes. N… 
Highly Cited
1975
Highly Cited
1975
N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin.
N-Trifluoroacetyladriamycin-14-valerate (AD 32), an analog of adriamycin, exhibits significantly greater antitumor activity than… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)